LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors

  LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently
  Utilized by an Estimated Two Million Unique Visitors Annually according to
  Google Analytics

- Company describes new product plans aimed at further monetizing these assets

Business Wire

ALAMEDA, Calif. -- February 11, 2013

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX),
announced today that according to Google Analytics, the Company’s databases
have attracted over two million unique visitors in the previous 12 months.
Since the announcement of the acquisition of Xennex in May 2012, LifeMap
launched LifeMap Discovery™, a database resource for stem cell research, and
MalaCards, a database with nearly 17,000 human disease entries. These assets,
combined with GeneCards^®, a compendium of human genes, provide an integrated
database suite with diverse commercial opportunities in science and medicine.
LifeMap Sciences holds the exclusive worldwide license to market GeneCards^®
and MalaCards from Yeda Research and Development Company Ltd., the commercial
arm of the Weizmann Institute of Science. LifeMap Discovery™ is a database
owned and developed by LifeMap Sciences. In this update, LifeMap describes the
nature of its current users, and outlines for the first time its goals for
2013 in marketing products to this user base.

According to Google Analytics, the sites have generated more than 2,000,000
unique visitors with more than 13,000,000 page views in the past 12 months.
LifeMap clients and partners include dozens of large, fee-paying
pharmaceutical and biotechnology companies, as well as leading government
patent offices, and its products are used free of charge by scientists at more
than a thousand academic institutions worldwide.

LifeMap achievements since the last update include:

  *Oct 2012 – Commercial launch of MalaCards
  *Nov 2012 – Commercial launch of LifeMap Discovery™
  *Nov 2012 – Release of GeneCards^® version 1.09
  *Nov 2012 – Launch of LifeMap BioReagents™ portal to market BioTime’s
    research products
  *Nov 2012 – Signing of definitive agreement with ProSpec-Tany TechnoGene, a
    biotechnology company specializing in production of bacterial-derived
    recombinant proteins, through which LifeMap Sciences will be offering
    recombinant proteins, many of which are related to stem cell research
  *Nov 2012 – Filing for patent protection of first intellectual property
    generated from LifeMap’s data-mining technology
  *Dec 2012 – First shared publication with BioTime in the peer-reviewed
    journal Regenerative Medicine
  *Jan 2013 – Publication in the peer-reviewed journal Bioinformatics of a
    research report describing a non-redundant compendium of human non-coding
    RNA, authored by GeneCards^® scientists under the supervision of Professor
    Doron Lancet from the Department of Molecular Genetics at the Weizmann
    Institute of Science
  *Feb 2013 – Release of MalaCards version 1.03

Key goals for 2013 include:

  *Expansion of LifeMap Discovery™ to incorporate additional cell and tissue
    types and associated gene expression signatures
  *Initiation of development of additional databases and services that will
    leverage significant and growing web traffic
  *Submission of manuscripts to peer-reviewed scientific journals for
  *Initiation of pay-per-view access to extensive microarray data on more
    than a 100 cultured somatic cell types and on approximately 100 PureStem™
    cell lines under several thousand differentiation conditions and their
    relationship to the developing human
  *Platform enhancement of GeneCards^® to enable improved data update and
    data mining, and development of applications for integrating GeneCards^®
    and MalaCards data with next-generation sequencing reports
  *Addition of new products for stem cell researchers to the LifeMap
    BioReagents™ e-commerce portal
  *Enhanced therapeutic discovery collaboration with BioTime and generation
    of several therapeutic product leads based on PureStem™ human stem-cell
    derived progenitors

“In recognition of the large and growing number of life sciences and medical
professionals using our database suite, we plan to roll out a series of
additional resources that will include subscription and pay-for-use products.
We will continue our support of academic researchers with free products to
meet their career and research needs,” said David Warshawsky, PhD, CEO of
LifeMap. “By leveraging our leading resources and large user base, we look
forward to realizing LifeMap’s potential for significant revenue growth.”

“We are witnessing the unification of the fields of genomics, cell biology,
and medicine,” said Michael West, PhD, CEO of BioTime and Chief Scientific
Officer of LifeMap. “As a result, professionals in one field increasingly
require instant access to large amounts of data from the other fields. LifeMap
is fulfilling BioTime’s strategic goals, on the one hand by generating
near-term revenue to balance the longer-term nature of our cell-based
therapies, and on the other by building foundational tools integral to the
future of medicine.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ ( core technology and business is based on
its integrated database suite, the discovery platform for biomedical and
stem-cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
internet marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. BioTime Acquisition Corporation is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents, and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be obtained at

About the Weizmann Institute of Science and GeneCards

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's
top-ranking multidisciplinary research institutions. Noted for its
wide-ranging exploration of the natural and exact sciences, the Institute is
home to 3,000 scientists, postdoctoral fellows, Ph.D. and M.Sc. students, and
scientific, technical and administrative staff. In addition, visiting
scientists and their families – over 500 from 35 countries in 2010 are
regularly hosted at the Institute. The Institute was founded in 1934 following
a donation to Dr. Chaim Weizmann, a noted biochemist and biotechnologist, who
envisioned the establishment of a world-class scientific research center in
Israel, and later also became the first President of the State of Israel.
Weizmann Institute’s Feinberg Graduate School was established in 1958, where
about 1000 M.Sc. and Ph.D. students are enrolled in studies covering the
Institute’s 18 departments, which are grouped into five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute’s technology transfer arm, Yeda Research and
Development Co. was the first company of its kind in Israel, and is currently
one of the most successful worldwide. Institute research efforts include the
search for new ways of fighting disease and hunger, examining leading
questions in mathematics and computer science, probing the physics of matter
and the universe, creating novel materials and developing new strategies for
protecting the environment. Particular excellence in bioinformatics and
systems biology is manifested, among others, in the GeneCards project,
initiated in 1996, under the leadership of Prof. Doron Lancet of the Dept. of
Molecular Genetics, Head of the Crown Human Genome Center. A team of 10 led by
Marilyn Safran continuously innovates and keeps GeneCards as a world-top human
gene compendium, automatically mining and integrating 100 worldwide web

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


LifeMap Sciences, Inc.
Kenneth Elsner, COO
781- 826- 7719
BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390, ext 367
Judith Segall
510-521-3390, ext 301
Press spacebar to pause and continue. Press esc to stop.